Inari Medical (NASDAQ:NARI) PT Lowered to $57.00

Inari Medical (NASDAQ:NARI – Free Report) had its price objective trimmed by Needham & Company LLC from $72.00 to $57.00 in a research note released on Wednesday, Benzinga reports. The brokerage currently has a buy rating on the stock. Several other analysts also recently commented on NARI. Truist Financial decreased their target price on shares […]

Related Keywords

United States ,Piper Sandler ,William Hoffman ,Mitchc Hill ,Handelsinvest Investeringsforvaltning ,Fifth Third Bancorp ,Benjaminf Edwards Company Inc ,Securities Exchange Commission ,Inari Medical Inc ,Third Bancorp ,Needham Company ,Nisa Investment Advisors ,Canaccord Genuity Group ,Inari Medical ,Free Report ,Genuity Group ,Moderate Buy ,Get Free Report ,Director William Hoffman ,Exchange Commission ,Management Fondsmaeglerselskab ,Investment Advisors ,Inari Medical Daily ,Nasdaq Nari ,Nari ,Medical ,Lower Price Target ,Needham Company Llc ,